BioEnterics® Intragastric Balloon (BIB®). Single Ambulatory Center Spanish Experience with 714 Consecutive Patients Treated with One or Two Consecutive Balloons

Overview

Journal Obes Surg

Date 2010 Mar 23

PMID 20306153

Citations 39

Authors

Gontrand Lopez-Nava

Miguel Angel Rubio

Susana Prados

Gabriela Pastor

Mar Rodriguez Cruz

Ena Companioni

Andres Lopez

Affiliations

Soon will be listed here.

Abstract

Background: The BioEnterics® Intragastric Balloon (BIB®) is a well-established device for temporary treatment in morbidly obese patients. The aim of this study is the evaluation, in a population of 714 consecutive outpatient setting cases, BIB® results in terms of weight loss and comorbidity change.

Methods: BIB® was positioned in all cases after diagnostic endoscopy. The device was inflated under direct endoscopic vision with saline solution (600-700 ml) and methylene blue (10 ml). Intubation was carried out in patients with body mass index (BMI) > 40 kg/m(2) affected by sleep apnea or chronic obstructive pulmonary disease. After 6 months, balloon removal was carried out, and patients were discharged with drug therapy and 1,000 kcal diet. More than 100 patients underwent a second consecutive balloon positioning. One month from the removal of the first BIB, patients were given a second BIB. Patients were followed up weekly. Mortality, complications and their treatment, postplacement symptoms, comorbidities, BMI, percentage of excess BMI loss (%EBL), and percentage of excess weight loss (%EWL) were considered. Data are expressed as mean ± standard deviation.

Results: From June 1, 2005, to May 31, 2007, 714 patients underwent BIB® placement (143 males/571 females; mean age, 38.4 ± 16.1; mean BMI, 37.6 ± 5.7 kg/m(2); mean EW, 56.3 ± 27.1 kg). After 6 months, mean BMI was 31.1 ± 7.2, mean %EWL was 41.6 ± 21.8, mean BMI loss was 6.5 ± 12.7, and mean %EBL was 44.5 ± 22.6. Of 714 patients, 112 underwent a second BIB placement. At the time of the second balloon placement, mean BMI was 32.9 ± 6.7 kg/m(2); range was 31-51. After the second balloon removal, mean BMI was 30.3 ± 7.2.

Conclusions: BIB® treatment is a safe and effective procedure for weight reduction, without mortality and with very low morbidity rates even in nonhospitalized patients. A second balloon can also be positioned without difficulties, achieving good results after 12 months of treatment.

Citing Articles

Is Gastric Balloon Implantation Still an Effective Procedure for the Management of Obesity and Associated Conditions? Findings from a Multi-Center Study.

Thaher O, Mansour R, Hukauf M, Croner R, Stroh C Obes Surg. 2024; 34(12):4350-4357.

PMID: 39527230 DOI: 10.1007/s11695-024-07552-3.

The Swallowable Intragastric Balloon Combined with Lifestyle Coaching: Short-Term Results of a Safe and Effective Weight Loss Treatment for People Living with Overweight and Obesity.

Jense M, Palm-Meinders I, Sanders B, Boerma E, Greve J Obes Surg. 2023; 33(6):1668-1675.

PMID: 37012502 PMC: 10234894. DOI: 10.1007/s11695-023-06573-8.

Nutritional Management and Role of Multidisciplinary Follow-Up after Endoscopic Bariatric Treatment for Obesity.

Negi A, Asokkumar R, Ravi R, Lopez-Nava G, Bautista-Castano I Nutrients. 2022; 14(16).

PMID: 36014956 PMC: 9416269. DOI: 10.3390/nu14163450.

Endoscopic Treatment of Obesity and Nutritional Aspects of Bariatric Endoscopy.

Kral J, Machytka E, Horka V, Selucka J, Dolecek F, Spicak J Nutrients. 2021; 13(12).

PMID: 34959819 PMC: 8703836. DOI: 10.3390/nu13124268.

Six intragastric balloons: Which to choose?.

Stavrou G, Shrewsbury A, Kotzampassi K World J Gastrointest Endosc. 2021; 13(8):238-259.

PMID: 34512874 PMC: 8394181. DOI: 10.4253/wjge.v13.i8.238.

References

Melissas J, Mouzas J, Filis D, Daskalakis M, Matrella E, Papadakis J . The intragastric balloon - smoothing the path to bariatric surgery. Obes Surg. 2006; 16(7):897-902. DOI: 10.1381/096089206777822188. View

Loffredo A, Cappuccio M, De Luca M, de Werra C, Galloro G, Naddeo M . Three years experience with the new intragastric balloon, and a preoperative test for success with restrictive surgery. Obes Surg. 2001; 11(3):330-3. DOI: 10.1381/096089201321336700. View

Genco A, Cipriano M, BACCI V, Cuzzolaro M, Materia A, Raparelli L . BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes (Lond). 2005; 30(1):129-33. DOI: 10.1038/sj.ijo.0803094. View

Roman S, Napoleon B, Mion F, Bory R, Guyot P, DOrazio H . Intragastric balloon for "non-morbid" obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004; 14(4):539-44. DOI: 10.1381/096089204323013587. View

Schapiro M, Benjamin S, Blackburn G, Frank B, Heber D, Kozarek R . Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida, March 19-21, 1987. Gastrointest Endosc. 1987; 33(4):323-7. DOI: 10.1016/s0016-5107(87)71611-3. View

De Waele B, Reynaert H, Urbain D, Willems G . Intragastric balloons for preoperative weight reduction. Obes Surg. 2000; 10(1):58-60. DOI: 10.1381/09608920060674139. View

Adams K, Schatzkin A, Harris T, Kipnis V, Mouw T, Ballard-Barbash R . Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006; 355(8):763-78. DOI: 10.1056/NEJMoa055643. View

Meshkinpour H, Hsu D, Farivar S . Effect of gastric bubble as a weight reduction device: a controlled, crossover study. Gastroenterology. 1988; 95(3):589-92. DOI: 10.1016/s0016-5085(88)80002-7. View

Nieben O, Harboe H . Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet. 1982; 1(8265):198-9. DOI: 10.1016/s0140-6736(82)90762-0. View

10.

McFarland R, Grundy A, Gazet J, Pilkington T . The intragastric balloon: a novel idea proved ineffective. Br J Surg. 1987; 74(2):137-9. DOI: 10.1002/bjs.1800740222. View

11.

Mathus-Vliegen E, Tytgat G . Intragastric balloons for morbid obesity: results, patient tolerance and balloon life span. Br J Surg. 1990; 77(1):76-9. DOI: 10.1002/bjs.1800770127. View

12.

Weiner R, Gutberlet H, Bockhorn H . Preparation of extremely obese patients for laparoscopic gastric banding by gastric-balloon therapy. Obes Surg. 1999; 9(3):261-4. DOI: 10.1381/096089299765553133. View

13.

Pasulka P, Bistrian B, Benotti P, Blackburn G . The risks of surgery in obese patients. Ann Intern Med. 1986; 104(4):540-6. DOI: 10.7326/0003-4819-104-4-540. View

14.

Totte E, Hendrickx L, Pauwels M, Van Hee R . Weight reduction by means of intragastric device: experience with the bioenterics intragastric balloon. Obes Surg. 2001; 11(4):519-23. DOI: 10.1381/096089201321209459. View

15.

Ramhamadany E, Fowler J, BAIRD I . Effect of the gastric balloon versus sham procedure on weight loss in obese subjects. Gut. 1989; 30(8):1054-7. PMC: 1434178. DOI: 10.1136/gut.30.8.1054. View

16.

Deitel M . How much weight loss is sufficient to overcome major co-morbidities?. Obes Surg. 2002; 11(6):659. DOI: 10.1381/09608920160558524. View

17.

Genco A, Balducci S, Bacci V, Materia A, Cipriano M, Baglio G . Intragastric balloon or diet alone? A retrospective evaluation. Obes Surg. 2008; 18(8):989-92. DOI: 10.1007/s11695-007-9383-9. View

18.

Calle E, Thun M, Petrelli J, Rodriguez C, Heath Jr C . Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999; 341(15):1097-105. DOI: 10.1056/NEJM199910073411501. View

19.

Pinkney J, Sjostrom C, Gale E . Should surgeons treat diabetes in severely obese people?. Lancet. 2001; 357(9265):1357-9. DOI: 10.1016/S0140-6736(00)04524-4. View

20.

. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991; 115(12):956-61. View